Patents by Inventor Douglas Orsi

Douglas Orsi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted heterocyclic compounds and therapeutic uses thereof
    Patent number: 12692261
    Abstract: Compounds of formula (I), process for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: July 28, 2026
    Assignees: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Volker Schulze, Anne Mengel, Clara Adelaide Faria Alvares De Lemos, Sven Christian, Ulf Bömer, Roman Hillig, Christian Lechner, Jérémie Xavier Mortier, Stefan Kaulfuss, Steven Corsello, Katarzyna Handing, Amael Madec, Laura Furst, Mrinal Shekhar, Markus Berger, Rajesha Rupaimoole, Philip Lienau, Douglas Orsi, David McKinney, Krzysztof Brzezinka
  • Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof
    Patent number: 12565496
    Abstract: Compounds of formula (I), process for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: March 3, 2026
    Assignees: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Volker Schulze, Anne Mengel, Adelaide Clara Faria Alvares De Lemos, Sven Christian, Ulf Bömer, Roman Hillig, Christian Lechner, Jérémie Xavier Mortier, Stefan Kaulfuss, Steven Corsello, Katarzyna Handing, Amael Madec, Laura Furst, Mrinal Shekhar, Markus Berger, Rajesha Rupaimoole, Philip Lienau, Douglas Orsi, David McKinney, Krzysztof Brzezinka
  • 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER
    Publication number: 20260035365
    Abstract: The present invention relates to 1H-pyrrolo[3,2-b]pyridine derivatives of formula (I) as irreversible inhibitors of mutant EGFR for the treatment of cancer. An exemplary compound is e.g. N-[2-({4-[3-(4-fluorophenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyri-din-3-yl}oxy)ethyl]prop-2-enamide (example 1). Pharmacological data of exemplary compounds is provided (AA). mutEGFR mutEGFR (D770_N771insSVD) (D770_N771insNPG, kinase assay T790) kinase assay Example IC50 IC50 No. [mol/l] [mol/l] 1 4.14E?07 6.06E?07 2 4.61E?07 7.51E?07 3 2.84E?06 3.41E?06 4 7.58E?09 1.
    Type: Application
    Filed: August 1, 2023
    Publication date: February 5, 2026
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan Siegel, Simon Anthony Herbert, Carsten Schmeck, Franziska Siegel, Jeremie Xavier G. Mortier, Stefanie Zimmermann, Daniel Korr, Ulf Bömer, Jens Schröder, Christian Lechner, Laura Evans, Douglas Orsi, Heidi Greulich, Matthew Meyerson, Alexandra Gould
  • SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS
    Publication number: 20250188075
    Abstract: The invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and associated methods of treating cancer.
    Type: Application
    Filed: January 27, 2023
    Publication date: June 12, 2025
    Inventors: Douglas Orsi, Florence F. Wagner, Steven Corsello, Mrinal Shekhar, Katarzyna Handing, Steven James Ferrara, David McKinney, Volker Schulze, Anne Mengel, Adelaide Clara Faria Alvares De Lemos, Sven Christian, Ulf Bömer, Roman Hillig, Christian Lechner, Jérémie Xavier Mortier, Stefan Kaulfuss, Rajesha Rupaimoole, Philip Lienau, Krzysztof Brzezinka, Markus Berger
  • Covalent PPARG inverse-agonists
    Publication number: 20240150277
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: May 9, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Knut EIS, Timo STELLFELD, Léa Aurelie BOUCHÉ, Elisabeth POOK, Joseph Peter BLUCK, Philip LIENAU, Constantia PANTELIDOU, Isabel Sophie JERCHEL-FURAU, Ulf BRÜEGGEMEIER, Sven CHRISTIAN, Detlev SÜLZLE, Anders Roland FRIBERG, Simon HOLTON, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Douglas ORSI, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF
    Publication number: 20230391769
    Abstract: Compounds of formula (I), process for their production and their use as pharmaceuticals.
    Type: Application
    Filed: July 27, 2021
    Publication date: December 7, 2023
    Inventors: Volker Schulze, Anne Mengel, Adelaide Clara Faria Alvares De Lemos, Sven Christian, Ulf Bömer, Roman Hillig, Christian Lechner, Jérémie Xavier Mortier, Stefan Kaulfuss, Steven Corsello, Katarzyna Handing, Amael Madec, Laura Furst, Mrinal Shekhar, Markus Berger, Rajesha Rupaimoole, Philip Lienau, Douglas Orsi, David McKinney, Krzysztof Brezezinka
  • SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20230339939
    Abstract: Compounds of formula (I), process for their production and their use as pharmaceuticals.
    Type: Application
    Filed: July 27, 2021
    Publication date: October 26, 2023
    Inventors: Volker Schulze, Anne Mengel, Adelaide Clara Faria Alvares De Lemos, Sven Christian, Ulf Bömer, v Hillig, Christian Lechner, Jérémie Xavier Mortier, Stefan Kaulfuss, Steven Corsello, Katarzyna Handing, Amael Madec, Laura Furst, Mrinal Shekhar, Markus Berger, Rajesha Rupaimoole, Philip Lienau, Douglas Orsi, David McKinney, Krzysztof Brezezinka